<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02389374</url>
  </required_header>
  <id_info>
    <org_study_id>PR-14053</org_study_id>
    <nct_id>NCT02389374</nct_id>
  </id_info>
  <brief_title>A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh</brief_title>
  <official_title>A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of Glucose-6-dehydrogenase Status in South-east Bangladesh</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menzies School of Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Centre for Diarrhoeal Disease Research, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Menzies School of Health Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study assessing safety and efficacy of current national guidelines for the
      treatment of uncomplicated malaria in Bangladesh as well as to assess the G6PD status among
      the enrolled patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The national guidelines for the treatment of uncomplicated malaria in Bangladesh currently
      recommend a standard dose of artemether-lumefantrine followed by a single dose of primaquine
      for P. falciparum malaria and a three day course of chloroquine followed by 14 days of
      primaquine for vivax malaria.Currently the national treatment guidelines do not include any
      testing for G6PD deficiency before treatment with primaquine. In order to guarantee safe and
      efficacious treatment for all patients diagnosed with uncomplicated malaria in Bangladesh, it
      is essential to monitor the effectiveness and safety of the recommended treatment guidelines.
      This trial therefore evaluates the local efficacy and safety of the current first line
      treatment and assesses the G6PD status of the enrolled patients.

      Patients with uncomplicated malaria attending the health care center, who meet the study
      inclusion criteria will be enrolled, treated on site and followed up for 28 days. The
      follow-up will consist of a fixed schedule of check-up visits and corresponding clinical and
      laboratory examinations. The study will provide efficacy data for both
      artemether-lumefantrine and chloroquine and will generate data on G6PD status in the region,
      which will provide vital information for policy makers in regards to the wider roll out of
      primaquine for the radical cure of vivax malaria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Proportion of Adverse and Serious Adverse Events Following Unsupervised Primaquine Treatment</measure>
    <time_frame>during follow up (day 28)</time_frame>
    <description>The proportion of adverse and serious adverse events following unsupervised primaquine treatment until day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Receiving Blood Transfusion and With Severe Anaemia (Hb&lt;7g/dl)</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional Change in Hb Between Baseline and Day 9 and 16</measure>
    <time_frame>day 0 and 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Anaemia Less Than 8g/dl on Day 2</measure>
    <time_frame>on day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Any Parasitemia on Day 3 After Treatment</measure>
    <time_frame>day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Fever on Day 2 After Treatment</measure>
    <time_frame>day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of Parasitaemia Within 16 Days of Follow up</measure>
    <time_frame>day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Adhering to 14 Days of Primaquine Treatment in the Vivax Cohort as Measured by Pill Count</measure>
    <time_frame>day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Distribution of G6PD Activity Measured in U/gHb Among All Malaria Patients</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Type of Variants of the G6PD Gene Within the Study Population</measure>
    <time_frame>day 0 or 1</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">181</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>chloroquine primaquine 14days</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>artemether-lumefantrine primaquine 1day</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>artemether-lumefantrine primaquine 14days</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chloroquine</intervention_name>
    <description>standard dose</description>
    <arm_group_label>chloroquine primaquine 14days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine combination</intervention_name>
    <description>standard dose</description>
    <arm_group_label>artemether-lumefantrine primaquine 1day</arm_group_label>
    <arm_group_label>artemether-lumefantrine primaquine 14days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine</intervention_name>
    <description>single dose</description>
    <arm_group_label>artemether-lumefantrine primaquine 1day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine</intervention_name>
    <description>14 days</description>
    <arm_group_label>chloroquine primaquine 14days</arm_group_label>
    <arm_group_label>artemether-lumefantrine primaquine 14days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 12 months

          -  P. vivax or P. falciparum monoinfection or P.v. / P.f. mixed infection

          -  Presence of axillary temperature ≥ 37.5°C or history of fever during the past 24 hrs

          -  Ability to swallow oral medication.

          -  Ability and willingness to comply with the study protocol for the duration of the
             study

          -  Informed consent/assent from the patient or from a parent or guardian in the case of
             children.

        Exclusion Criteria:

          -  Presence of general danger signs in children aged under 5 years or signs of severe
             malaria according to the definitions of WHO

          -  Presence of severe malnutrition

          -  Acute anaemia &lt;8g/dL

          -  Regular medication, which may interfere with antimalarial pharmacokinetics

          -  History of hypersensitivity reactions or contraindications to any of the drug(s)
             tested or used as alternative treatment(s)

          -  A positive pregnancy test or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <results_first_submitted>January 31, 2017</results_first_submitted>
  <results_first_submitted_qc>July 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2017</results_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Primaquine</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chloroquine Primaquine 14days</title>
          <description>P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines
chloroquine: standard dose
Primaquine: 14 days</description>
        </group>
        <group group_id="P2">
          <title>Artemether-lumefantrine Primaquine 1day</title>
          <description>P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: single dose</description>
        </group>
        <group group_id="P3">
          <title>Artemether-lumefantrine Primaquine 14days</title>
          <description>mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chloroquine Primaquine 14days</title>
          <description>P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines
chloroquine: standard dose
Primaquine: 14 days</description>
        </group>
        <group group_id="B2">
          <title>Artemether-lumefantrine Primaquine 1day</title>
          <description>P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: single dose</description>
        </group>
        <group group_id="B3">
          <title>Artemether-lumefantrine Primaquine 14days</title>
          <description>mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: 14 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="115"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="181"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18" lower_limit="11" upper_limit="27"/>
                    <measurement group_id="B2" value="22" lower_limit="14" upper_limit="30"/>
                    <measurement group_id="B3" value="14" lower_limit="7" upper_limit="26"/>
                    <measurement group_id="B4" value="20" lower_limit="11" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bangladesh</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of Adverse and Serious Adverse Events Following Unsupervised Primaquine Treatment</title>
        <description>The proportion of adverse and serious adverse events following unsupervised primaquine treatment until day 28</description>
        <time_frame>during follow up (day 28)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroquine Primaquine 14days</title>
            <description>P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines
chloroquine: standard dose
Primaquine: 14 days</description>
          </group>
          <group group_id="O2">
            <title>Artemether-lumefantrine Primaquine 1day</title>
            <description>P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: single dose</description>
          </group>
          <group group_id="O3">
            <title>Artemether-lumefantrine Primaquine 14days</title>
            <description>mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Adverse and Serious Adverse Events Following Unsupervised Primaquine Treatment</title>
          <description>The proportion of adverse and serious adverse events following unsupervised primaquine treatment until day 28</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Receiving Blood Transfusion and With Severe Anaemia (Hb&lt;7g/dl)</title>
        <time_frame>day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroquine Primaquine 14days</title>
            <description>P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines
chloroquine: standard dose
Primaquine: 14 days</description>
          </group>
          <group group_id="O2">
            <title>Artemether-lumefantrine Primaquine 1day</title>
            <description>P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: single dose</description>
          </group>
          <group group_id="O3">
            <title>Artemether-lumefantrine Primaquine 14days</title>
            <description>mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Receiving Blood Transfusion and With Severe Anaemia (Hb&lt;7g/dl)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fractional Change in Hb Between Baseline and Day 9 and 16</title>
        <time_frame>day 0 and 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroquine Primaquine 14days</title>
            <description>P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines
chloroquine: standard dose
Primaquine: 14 days</description>
          </group>
          <group group_id="O2">
            <title>Artemether-lumefantrine Primaquine 1day</title>
            <description>P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: single dose</description>
          </group>
          <group group_id="O3">
            <title>Artemether-lumefantrine Primaquine 14days</title>
            <description>mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Fractional Change in Hb Between Baseline and Day 9 and 16</title>
          <units>percent change Hb</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline to day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" lower_limit="-6.2" upper_limit="1.5"/>
                    <measurement group_id="O2" value="-7.7" lower_limit="-11.2" upper_limit="-4.2"/>
                    <measurement group_id="O3" value="-13.8" lower_limit="-22.1" upper_limit="-5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline to day 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-6.1" upper_limit="5.1"/>
                    <measurement group_id="O2" value="NA">No visit on day 16</measurement>
                    <measurement group_id="O3" value="-8.3" lower_limit="-20.2" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Anaemia Less Than 8g/dl on Day 2</title>
        <time_frame>on day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroquine Primaquine 14days</title>
            <description>P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines
chloroquine: standard dose
Primaquine: 14 days</description>
          </group>
          <group group_id="O2">
            <title>Artemether-lumefantrine Primaquine 1day</title>
            <description>P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: single dose</description>
          </group>
          <group group_id="O3">
            <title>Artemether-lumefantrine Primaquine 14days</title>
            <description>mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Anaemia Less Than 8g/dl on Day 2</title>
          <units>participants with Hb under 8g/dl</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Any Parasitemia on Day 3 After Treatment</title>
        <time_frame>day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroquine Primaquine 14days</title>
            <description>P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines
chloroquine: standard dose
Primaquine: 14 days</description>
          </group>
          <group group_id="O2">
            <title>Artemether-lumefantrine Primaquine 1day</title>
            <description>P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: single dose</description>
          </group>
          <group group_id="O3">
            <title>Artemether-lumefantrine Primaquine 14days</title>
            <description>mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Any Parasitemia on Day 3 After Treatment</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Fever on Day 2 After Treatment</title>
        <time_frame>day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroquine Primaquine 14days</title>
            <description>P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines
chloroquine: standard dose
Primaquine: 14 days</description>
          </group>
          <group group_id="O2">
            <title>Artemether-lumefantrine Primaquine 1day</title>
            <description>P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: single dose</description>
          </group>
          <group group_id="O3">
            <title>Artemether-lumefantrine Primaquine 14days</title>
            <description>mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Fever on Day 2 After Treatment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence of Parasitaemia Within 16 Days of Follow up</title>
        <time_frame>day 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroquine Primaquine 14days</title>
            <description>P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines
chloroquine: standard dose
Primaquine: 14 days</description>
          </group>
          <group group_id="O2">
            <title>Artemether-lumefantrine Primaquine 1day</title>
            <description>P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: single dose</description>
          </group>
          <group group_id="O3">
            <title>Artemether-lumefantrine Primaquine 14days</title>
            <description>mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence of Parasitaemia Within 16 Days of Follow up</title>
          <units>Recurrences of Parsitaemia</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Adhering to 14 Days of Primaquine Treatment in the Vivax Cohort as Measured by Pill Count</title>
        <time_frame>day 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroquine Primaquine 14days</title>
            <description>P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines
chloroquine: standard dose
Primaquine: 14 days</description>
          </group>
          <group group_id="O2">
            <title>Artemether-lumefantrine Primaquine 1day</title>
            <description>P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: single dose</description>
          </group>
          <group group_id="O3">
            <title>Artemether-lumefantrine Primaquine 14days</title>
            <description>mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Adhering to 14 Days of Primaquine Treatment in the Vivax Cohort as Measured by Pill Count</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="NA">this outcome was only collected for the other two arms</measurement>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Distribution of G6PD Activity Measured in U/gHb Among All Malaria Patients</title>
        <time_frame>day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Malaria Patients</title>
            <description>single Arm/Group for all participants</description>
          </group>
        </group_list>
        <measure>
          <title>The Distribution of G6PD Activity Measured in U/gHb Among All Malaria Patients</title>
          <units>U/gHb</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.82" lower_limit="6.62" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Type of Variants of the G6PD Gene Within the Study Population</title>
        <time_frame>day 0 or 1</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Chloroquine Primaquine 14days</title>
          <description>P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines
chloroquine: standard dose
Primaquine: 14 days</description>
        </group>
        <group group_id="E2">
          <title>Artemether-lumefantrine Primaquine 1day</title>
          <description>P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: single dose</description>
        </group>
        <group group_id="E3">
          <title>Artemether-lumefantrine Primaquine 14days</title>
          <description>mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines
Artemether-lumefantrine combination: standard dose
Primaquine: 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Benedikt Ley</name_or_title>
      <organization>Menzies School of Health Research</organization>
      <phone>889468643</phone>
      <email>benedikt.ley@menzies.edu.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

